

Coding and Billing Information

INTERCEPT® platelet and plasma products administered in the outpatient setting (Psoralen-treated; pathogen reduced)

Below are the Healthcare Common Procedure Coding System (HCPCS) codes to use for third party payer billing of INTERCEPT platelet and plasma products provided in the hospital outpatient treatment setting:

HCPCS Code	Long Descriptor	Effective Date
P9070	Plasma, pooled multiple donor, pathogen reduced, frozen, each unit	1/1/2016
P9071	Plasma (single donor), pathogen reduced, frozen, each unit	1/1/2016
P9073	Platelets, pheresis, pathogen reduced, each unit	1/1/2018

Effective 1/1/2018, HCPCS P9073 replaced HCPCS Q9988 to bill pathogen reduced apheresis platelets. HCPCS Q9988 became inactive effective 1/1/2018.

Standard billing practices apply to transfusion procedures used to administer pathogen reduced, psoralen-treated INTERCEPT platelet and plasma products administered in the outpatient treatment setting.

Standard billing practices apply to INTERCEPT platelet and plasma products administered in the hospital inpatient treatment setting.

About INTERCEPT platelet and plasma products

Pathogen reduced apheresis platelet components prepared using the INTERCEPT Blood System for Platelets (“INTERCEPT platelets,” “psoralen-treated platelets”) are intended to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD).

Pathogen reduced whole blood derived or apheresis plasma components prepared using the INTERCEPT Blood System for Plasma (“INTERCEPT plasma,” “psoralen-treated plasma”) are intended to reduce the risk of TTI and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD).

For questions about the INTERCEPT Blood System, contact Cerus Corporation by phone (855) 835-3523 or visit www.intercept-usa.com.

References:

- The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation; September 6, 2022.
- The INTERCEPT Blood System for Plasma Package Insert, Cerus Corporation; September 6, 2022.
- CY2020 Hospital Outpatient Prospective Payment – Notice of Final Rulemaking with Comment: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1717-FC>
- The information provided here is for informational purposes only and may be subject to change. Always check with individual third party payers to verify their requirements for billing these products and associated transfusion services.

Contraindications

Contraindicated for preparation of platelet or plasma components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet or plasma components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

Warnings and Precautions

Only INTERCEPT Processing Sets are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet or plasma components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet or plasma components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

Amotosalen-treated plasma may cause the following adverse reaction: Cardiac Events. In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

Rx Only. See package inserts for full prescribing information.



GLOBAL HEADQUARTERS | 1220 Concord Avenue | Concord, CA US 94520 | 855.835.3523
www.cerus.com | www.intercept-usa.com

Rx only. See package insert for full prescribing information.